(2026) Age-stratified clinical characteristics and disability outcomes in neuromyelitis optica spectrum disorder: A cross-sectional study. Acta neurologica Belgica. ISSN 2240-2993 (Electronic) 0300-9009 (Linking)
Full text not available from this repository.
Abstract
BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system in individuals of any age group. Age-related differences may influence disease severity, treatment response, and long-term functional outcomes. However, age-related characteristics of pediatric-onset (PO-), early-onset (EO-), and late-onset (LO-) NMOSD remain incompletely understood. The purpose of this study was to compare these three groups in various features and to identify the relationship between age at initial disease presentation and disability profile in NMOSD. METHODS: This study included 72 AQP4-positive NMOSD patients in Isfahan, Iran, between March and November 2024. Patients were categorized based on age at NMOSD diagnosis into PO (< 18 years), EO (18-49 years), and LO (>/= 50 years) groups. Logistic regression analysis was used to evaluate the associations between age at NMOSD diagnosis and disability. RESULTS: Among 72 patients, 6 were classified as PO-NMOSD, 55 as EO-NMOSD, and 11 as LO-NMOSD. Age at NMOSD diagnosis was positively correlated with EDSS at disease diagnosis (r = 0.42, p < 0.001) and current EDSS (r = 0.37, p = 0.002). In multivariable analysis, older age at NMOSD diagnosis was significantly associated with both higher disability at diagnosis (OR = 1.14, p < 0.001) and current disability status (OR = 1.1, p < 0.001). CONCLUSION: Older age at NMOSD diagnosis may be associated with greater disability burden. Age at diagnosis may represent a relevant clinical factor when evaluating disability burden in NMOSD. Further prospective multicenter studies are warranted to better define longitudinal outcomes and prognostic factors in LO-NMOSD.
| Item Type: | Article |
|---|---|
| Keywords: | Disability Late-onset Neuromyelitis optica spectrum disorder Clinical trial number: Not applicable. Declaration of generative AI and AI-assisted technologies in the writing process: During the preparation of this work, the authors used ChatGPT in order to improve the readability and language of the manuscript. After using this service, the authors reviewed and edited the content as needed and take full responsibility for the content of the published article. Human Ethics and Consent to Participate: The ethics committee of Isfahan University of Medical Sciences approved the research protocol (IR.ARI.MUI.REC.1401.061). All procedures conformed to the ethical standards in the 1964 Helsinki Declaration. Informed consent was secured from all participants in this study. |
| Journal or Publication Title: | Acta neurologica Belgica |
| Journal Index: | Pubmed |
| Identification Number: | https://doi.org/10.1007/s13760-026-03179-6 |
| ISSN: | 2240-2993 (Electronic) 0300-9009 (Linking) |
| Depositing User: | خانم ناهید ضیائی |
| URI: | http://eprints.mui.ac.ir/id/eprint/34458 |
Actions (login required)
![]() |
View Item |


